Avantor, Inc. (NYSE:AVTR) is positioned for potential growth in the upcoming quarters, largely due to its robust product offerings. The company's encouraging second-quarter 2026 performance and progress in cost transformation initiatives further bolster this outlook. However, challenges persist in the VWR Distribution & Services segment, which remains a concern.
Year-to-date, Avantor's stock has risen by 35.2%, outpacing the industry's 5.1% growth and the S&P 500's 13.9% increase1. As a prominent provider of essential products and services, Avantor boasts a market capitalization of $10.6 billion. The company forecasts a 1.6% earnings growth over the next five years and expects continued business improvements. Notably, Avantor's earnings have exceeded the Zacks Consensus Estimate in three of the last four quarters, with an average surprise of 4.3%.
Factors Supporting Avantor's Growth
Revival Program and Execution Discipline: Avantor's company-wide framework, known as Avantor Revival, is designed to rejuvenate growth and enhance execution across various domains, including commercial performance, operations, and portfolio management. The second quarter of 2026 provided evidence of the program's positive impact on results.
The VWR segment achieved organic growth of 1.7% ahead of expectations, with management attributing over half of this improvement to strategic commercial actions. Although the Bioscience & Medtech Products (BMP) segment experienced a 5.6% organic decline, it reported double-digit order growth and a book-to-bill ratio of 1.1, supporting management's expectation of a return to growth in the latter half of 2026.
Management anticipates that VWR's growth will accelerate through the second half of the year, suggesting that execution gains are beginning to counterbalance mixed end-market conditions.
Product Portfolio: Avantor's extensive range of high-value specialty products, such as J.T. Baker high-purity chemicals and NuSil customized silicones, remains a key competitive advantage in the life sciences, healthcare, and advanced manufacturing markets. The company differentiates itself through integrated solutions that combine specialty products, services, and digital capabilities. The Avantor Business System further supports execution and continuous improvement across operations.
Digital initiatives are gaining momentum following enhancements to the VWR e-commerce platform, with improvements in direct traffic, conversion rates, and daily sales during the second quarter of 2026. Additionally, there has been a positive trend in demand for the specialty portfolio, including double-digit BMP order growth and a 1.1x book-to-bill ratio, driven by strength in Process Chemicals and Fluid Handling. Management expects these trends, along with ongoing investments in sourcing, pricing, and digital capabilities, to support BMP's growth in the second half of 2026.
Strong Second Quarter Results
Avantor concluded the second quarter of 2026 with results that exceeded expectations, with both earnings and revenues surpassing estimates. The company also raised its 2026 organic revenue growth and adjusted earnings guidance, reflecting stronger-than-expected performance and improved outlook for the second half of the year.
A key highlight of the quarter was the return of VWR Distribution & Services to organic growth ahead of schedule. This segment benefited from enhanced commercial execution, new business wins, improved e-commerce trends, and better engagement with both large global and small to mid-sized customers. The Bioscience & Medtech Products segment also performed near the high end of management's expectations, supported by strength in process chemicals, double-digit order growth, and a book-to-bill ratio of 1.1 times.
Challenges to Growth
Despite signs of improving demand across certain business areas, Avantor's recovery remains uneven. While the VWR Distribution & Services segment achieved 1.7% organic growth in the second quarter of 2026, the Bioscience & Medtech Products segment continued to lag with a 5.6% organic revenue decline. This was due to weaker performance in Fluid Handling, NuSil, Electronic Materials, and Serum, along with unfavorable customer ordering patterns and shipment comparisons. Although BMP posted double-digit order growth and a healthy 1.1x book-to-bill ratio, management's full-year organic growth outlook of negative 0.5% to positive 0.5% suggests that the rebound will be gradual and dependent on end-market demand and execution.
Estimate Trend
Avantor has experienced a stable estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for its earnings per share has remained steady at 81 cents2. The Zacks Consensus Estimate for third-quarter 2026 revenues is set at $1.64 billion, indicating a 1.1% increase from the previous year's reported figure.
Other notable stocks in the medical sector include OPKO Health (NASDAQ:OPK), Globus Medical (NYSE:GMED), and Merit Medical Systems (NASDAQ:MMSI), each with strong earnings performances in recent quarters.
Footnotes:
- Avantor's stock performance has significantly outpaced both its industry and the S&P 500 index year-to-date. Source.
- The Zacks Consensus Estimate for Avantor's earnings per share has remained stable over the past 30 days. Source.
Featured Image: DepositPhoto @ Haydmitriy